000			02198 a2200661 4500
005			20250517125847.0
264		0	_c20180221
008			201802s 0 0 eng d
022			_a1949-2553
024	7		_a10.18632/oncotarget.13458 _2doi
040			_aNLM _beng _cNLM
100	1		_aKumarakulasinghe, Nesaretnam Barr
245	0	0	_aEGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. _h[electronic resource]
260			_bOncotarget _cDec 2016
300			_a85542-85550 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aChi-Square Distribution
650	0	4	_aDatabases, Factual
650	0	4	_aDisease Progression
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Interactions
650	0	4	_aErbB Receptors _xantagonists & inhibitors
650	0	4	_aErlotinib Hydrochloride _xpharmacology
650	0	4	_aFemale
650	0	4	_aGefitinib
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aKarnofsky Performance Status
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultivariate Analysis
650	0	4	_aMutation
650	0	4	_aProportional Hazards Models
650	0	4	_aProtein Kinase Inhibitors _xadverse effects
650	0	4	_aProton Pump Inhibitors _xadverse effects
650	0	4	_aQuinazolines _xpharmacology
650	0	4	_aRetrospective Studies
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aSingapore
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aSyn, Nicholas
700	1		_aSoon, Yu Yang
700	1		_aAsmat, Atasha
700	1		_aZheng, Huili
700	1		_aLoy, En Yun
700	1		_aPang, Brendan
700	1		_aSoo, Ross Andrew
773	0		_tOncotarget _gvol. 7 _gno. 51 _gp. 85542-85550
856	4	0	_uhttps://doi.org/10.18632/oncotarget.13458 _zAvailable from publisher's website
999			_c26657837 _d26657837